Bipolar Disorder Treatment Market [By Drug Class (Mood Stabilizers, Anticonvulsants, Antipsychotic drugs, Antidepressant drugs, Antianxiety drugs); Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Beta Blockers)]; and Geography - Trend, Analysis and Forecast till 2025

报告摘要

这全球双相障碍治疗市场增长主要是由于疾病的发生增加。双相情感障碍，也被称为躁狂抑郁症，这是一种与情绪波动事件相关的疾病，从抑郁的低点延伸到躁狂高。精神状态的变化是一个人的心情高或低的原因。患有双相情感障碍的人可以在特定的时刻，快乐，快乐的工作中有精力充沛，突然转向绝望，悲伤或昏昏欲睡。由于这些不同的情绪或两极的心情，这种精神疾病被称为双极障碍。通过研究活动，观察到某些遗传因素对双相障碍的发展负责。拥有这种疾病家族史的人最有可能发展疾病。患有双相情感障碍的人可能会在他们的社会，学校或工作中妨碍他们的形象或个性。根据国家精神卫生研究院，双相情绪影响约570万成年人，每年约有2.6％的人口龄18岁或以上。然而，通过适当的药物和治疗，可以控制双极性疾病。 The treatment of a bipolar disorder includes psychotherapy and medications for mood stabilizers and antipsychotics.

增加政府以及私人支持来减少双相情感障碍，以大大提高全球市场增长

这全球双相障碍治疗市场is majorly driven by factors such as increasing prevalence of bipolar disorder. According to the National Institute of Mental Health, approximately 10 million people in the U.S. develop this illness sometimes during their lives. And about half of them never receive the correct diagnosis or treatment. Moreover, according to the World Health Organizations (WHO), bipolar disorder is the 6th leading cause of disability in the world. However, increase in consciousness for the treatment and diagnosis of bipolar disorder and unmet desires in the treatment of the disorder are the major drivers for the growth of the global bipolar disorder treatment market. Growing recognition of society for the mental illness is encouraging people to get a treatment for this disorder. In addition, advancement in technology to identify the genes responsible for this disease are another major factor driving the global growth of bipolar disorder treatment market. Increasing government support including the launch of Bipolar Disorder Phenome Database, funded by the National Institute of Mental Health (NIMH) to provide complete info concerning symptoms and signs of the illness has further contributed to the significant growth of the market. In addition, key players and medical institutions are also playing a vital role by leading continuous efforts in research development to produce novel drugs and treatments for bipolar disorder. For instance, the John Hopkins University of Medicine and Salk Institute for Biological Studies have launched an initiative in order to develop drug screening methods regarding bipolar disorder and schizophrenia.

However, factors such as side effects of anticonvulsants, strict regulatory outlines, and an inadequate number of approved anticonvulsants are factors anticipated to hamper the market growth.

全球双相障碍治疗市场Taxonomy:

这全球双相障碍治疗市场is segmented on the basis of drug class, Mechanism of Action, and geography.

On the basis of毒品课, the global bipolar disorder treatment market is segmented into:

• Mood Stabilizers
• 抗惊厥药
• 抗精神病药物
• 抗抑郁药物
• Antianxiety drugs

On the basis of行动机制, the global bipolar disorder treatment market is segmented into:

• 选择性血清素再摄取抑制剂
• 血清素脑肾上腺素再摄取抑制剂
• 三环抗抑郁药
• 单胺氧化酶抑制剂
• 苯二氮卓卓
• Beta Blockers

地理位置上，全球双相障碍治疗市场被分段为北美，欧洲，亚太地区，拉丁美洲和中东和非洲。

预计迫切需要疾病的疾病的发生旨在促进北美的市场增长

在地理的基础上，据估计，北美占据了双相障碍治疗市场的主要份额。主要市场份额是由于该地区的双相障碍患病率越来越普及。增加人口中的物质滥用趋势，睡眠不足，高应力水平是北美双相疾病的主要因素。此外，政府支持生成关注和双相障碍患者的患者也在该地区推动市场增长。例如，2016年，美国卫生和人类服务部的分支机构包括滥用和心理健康服务管理局（Samhsa）和心理健康服务中心（CMHS），扩大了其对心理健康处理和恢复的必威开户注册支持。这些举措提高了北美双相障碍治疗市场增长。

但是，亚太地区预计在预测期间占主导地位。预计患有这种疾病的人数的增加会增加对这种疾病治疗的需求。据谁，印度和中国患有大多数患有精神障碍，包括精神分裂症，焦虑和双相情感障碍的患者。作为结果，预计要求妥善治疗的人数负责亚太地区双相障碍治疗市场的增长。

Key players in global bipolar disorder treatment market:

• Glaxo Smithkline（GSK）
• Pfizer Inc.
• Janssen Pharmaceuticals.
• Eli Lilly and company
• allergan plc。
• Novartis AG
• ABBVIE Inc.
• Otsuka Holdings Co. Ltd
• Astazeneca.